Fill out the form to receive 10 reasons to choose quantitative TCR sequencing in immuno-oncology.
All fields marked with * are mandatory.
T-cells are components of the adaptive immune system that act as effectors of the immune response in multiple diseases – such as infectious diseases, auto-immune diseases and cancer.
In cancer, it is now clearly demonstrated that some tumors present antigens on their surface.
T lymphocytes can recognise these antigens thanks to the T-cell receptor (TCR), which is composed of two protein chains (α and β). Due to the huge variability of these genes, this receptor is unique to each naïve lymphocyte.
High-throughput sequencing of these genes
(TCR-Seq) can be used to characterise the T-cells repertoire by detecting individual T lymphocytes in biological samples.
An increasing number of treatments modulating
T lymphocyte activity have revolutionised the therapeutic landscape to fight and cure cancer.
Monitoring of T lymphocytes by TCR-Seq has been proposed as a strategy to predict and follow the efficacy of these treatments.
Quantitative TCR sequencing gives you a new perspective in your quest to new cancer immunotherapies.
Seqalis™ is THE company providing this novel quantitative solution. What’s more, we also propose customised scientific analysis and medical interpretation of the results.
This makes Seqalis™ a trustworthy partner in the immuno-oncology space.